All companies
Haemonetics Corporation logo

What smart money is saying about Haemonetics CorporationUnited States flag

HAE · Healthcare · Medical - Devices · Market cap $4.83B

3 funds in our archive have pitched Haemonetics Corporation — most recently Ariel Investments Small Cap Value in June 2026.

Company profile

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.

Get an email when a fund writes about it

Summarize with Warren AI
2
Reported positions
2
Bought
0
Sold
4
Letters

Position history

Between Q4 2024 and Q2 2026, 2 fund letters reported a position in Haemonetics Corporation2 opened or added to the position.

Fund letters reporting a position in Haemonetics Corporation, by quarter
QuarterLettersBoughtSoldTheses
Q2 20262201
Q4 20250001
Q4 20240001

Fund activity · 2 positions · 2 moves

Fund coverage · 3 theses

Read every full thesis on Haemonetics Corporation

Unlock all 3 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans
Share this ledger